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Abstract 25
Antibiotics have revolutionised the treatment of infectious disease and improved the 26 lives of billions of people worldwide over many decades. With the rise in 27 antimicrobial resistance (AMR) and corresponding lack of antibiotic development, we 28 find ourselves in dire need of alternative treatments. Bacteriocins are a class of 29 bacterially produced, ribosomally synthesised, antimicrobial peptides that may be 30 narrow or broad in their spectrums of activity. Animal models have demonstrated the 31 safety and efficacy of bacteriocins in treating a broad range of infections, however, 32 one of the principal drawbacks has been their relatively narrow spectra as compared 33 with small molecule antibiotics. In an era where we are beginning to appreciate the 34 role of the microbiota in human and animal health, the fact that bacteriocins cause 35 much less collateral damage to the host microbiome makes them a highly desirable 36 therapeutic. This review makes a case for the implementation of bacteriocins as 37 therapeutic antimicrobials, either alone or in combination with existing antibiotics to 38 alleviate the AMR crisis and to lessen the impact of antibiotics on the host 39 microbiome. 40
Introduction 46
Antimicrobial resistance (AMR) has been recognised as one of the major threats to 47 public health in the 21 st century. In a report commissioned by the UK government in 48 2014, it was estimated that AMR could be responsible for 10 million deaths 49 worldwide by 2050, with a global financial cost of $100 trillion (1) . Meanwhile the 50 Centers for Disease Control and Prevention (CDC) estimates the annual cost of AMR 51 in the US to range from $20 billion in direct healthcare costs to $35 billion in 52 additional costs to society due to lost productivity (2). Apart from the human and 53 financial costs associated with AMR, there are also ethical considerations that need to 54 be addressed surrounding how we as a society respond and deal with the AMR crisis 55
(3). There are multiple reasons for the present AMR crisis, but significant factors 56 include the incorrect/indiscriminate administration and use of antibiotics and a dry 57 antibiotic development pipeline (4, 5). The CDC also recently estimated that in the 58 US approximately 50% of antibiotics are incorrectly prescribed. Moreover, the use of 59 antibiotics in agriculture has continued, despite undeniable evidence that this practice 60 adds to the antimicrobial resistance crisis. Resistance to a key "last-resort" antibiotic, 61 colisitin, has been observed in the US, Europe and Asia (6-8). We have also seen the 62 rapid spread of resistance to another "last resort" class of antibiotics, the carbapenems 63 (9). With the emergence of these new resistant strains and the emergence of pan-64 resistant bacteria, it is safe to say we have truly arrived in the much predicted post-65 antibiotic era (10). 66
67
It is important that we acknowledge that broad-spectrum antibiotic therapy has 68 revolutionised the treatment of infectious diseases within the last century, but we must 69 also admit to unintended consequences of antibiotic use, such as potentially negative 70 effects on the host microbiome and their potential toxicity (5, 11) . Although the field 71 of microbiome research is in its infancy relative to that of antibiotic therapy, evidence 72 strongly suggests that the composition of the microbiome can be an indicator of health 73 and is likely to be involved in many aspects of human health and disease (12). Strides 74 in DNA sequencing technology and bioinformatics have increased our understanding 75 of the role of the microbiome in a variety of disease states. Indeed the administration 76 of antibiotics in early life and the subsequent disruption of the microbiota may 77 contribute to risk of obesity in later life (13, 14) . Furthermore, when subjected to 78 broad-spectrum antibiotic therapy, non-target commensal microbes may evolve and/or 79 acquire resistance mechanisms to evade the effects of the antibiotic, thereby 80 contributing to the antibiotic resistance crisis. 81
82
Bacteriocins represent a class of powerful antimicrobial peptides that may provide at 83 least part of a solution to the AMR crisis. We aim to demonstrate their efficacy in the 84 treatment of infectious disease and their reduced impact on the host microbiome by 85 comparison to broad-spectrum antibiotic therapy. 86 87 Bacteriocins: potent antimicrobial peptides 88 Many excellent reviews have been written about bacteriocins (11, 15, 16) , but in 89 brief they are a diverse group of peptides that may be classified into three distinct 90 groups; class I (modified), class II (unmodified or cyclic) and Class III (>10kDa 91 peptides). Apart from their potent antimicrobial activity (with minimum inhibitory 92 concentrations [MIC's] often in the nanomolar range) they have also been shown to 93 have antiviral (17), anticancer (18) and immunomodulatory properties (19) . 94 peptides are also present in this class of antimicrobials (e.g. nisin and lacticin 3147 96 inhibit a wide range of Gram-positive bacteria). As a result these peptides may be 97 suitable for treating infections of unknown aetiology, using broad-spectrum 98 bacteriocins, or may allow more precise targeting of known infectious agents using 99 highly active narrow spectrum bacteriocins. Bacteriocins are gene encoded, which 100 makes them amenable to genetic alterations to improve functional characteristics. 101
Furthermore, their toxicity is low and they may be administered as either purified 102 peptide or produced in situ by bacteriocin producing probiotic bacteria (11) . 103
Bacteriocins are also known to interact with a variety of receptors, which are different The microbiota perspective 113 The term "superorganism" or "holobiont" has commonly been applied to describe the 114 relationship that exists between humans and its commensal microbes and viruses (23). 115
Understanding the role of the microbiota in health and protecting its diversity during 116 the treatment of infectious disease is a key element of why bacteriocins may be 117 suitable as alternatives to antibiotics. 118
The two-peptide sactibiotic bacteriocin, Thuricin CD, is a narrow spectrum 120 bacteriocin. Thuricin CD is highly active against one of the main causative agent of 121 antibiotic associated diarrhoea (AAD), Clostridium difficile, which is responsible for 122 20-30% of AAD cases (24). Briefly, AAD is caused by a disruption of the microbiota 123 (often referred to as dysbiosis) following broad spectrum antibiotic treatment, and 124 notably has a recurrence rate of 15-60% (25). Thuricin CD was shown to exhibit 125 comparable activity to both vancomycin and metronidazole (two antibiotics used for 126 the treatment of AAD which has progressed to C. difficile associated disease, CDAD). 127
Importantly, it showed almost no effect on microbial diversity when compared to both 128 metronidazole and vancomycin in a distal colon model (26). The modified R-Type 129 bacteriocin, Av-CD291.2, has also been shown to prophylactically prevent 130 colonization of C. difficile in a mouse model without perturbing the microbiota (27). 131
There are other broad spectrum bacteriocins which are attractive therapeutic agents by 132 virtue of their activity against C. difficile, but while the broad spectrum lantibiotic 133 lacticin 3147 is effective at killing C. difficile, it has a significant impact on the 134 resident microbiome populations such as Bifidobacterium, Lactobacillus and 135
Enterococcus species (28). It has also been shown that a commercially available 136 product containing the lantibiotic nisin, Nisaplin ® , can eliminate a C. difficile 137 infection when added at a concentration of 20X MIC in a simulated human colon 138 model. However a significant decrease in the total microbiota count was observed, 139
with Gram-positives being adversely affected (29). 140 141 Notably, in recent years the emergence of Vancomycin Resistant Enterococci (VRE) 142 has become a great concern and therefore raises the issues surrounding the efficacy of 143 treating CDAD with vancomycin if it presents a risk to the general population and the 144 spread of antibiotic resistance. In this light, the treatment of CDAD with bacteriocins 145 could be a valuable alternative to vancomycin. When VRE development has taken 146 place, it has been shown that mice colonised with VRE can be decolonized through 147 the use of an Enterococcus probiotic containing a conjugation defective plasmid 148 which produces a bacteriocin named . 149 150 A defensin-like bacteriocin, bactofencin A, displays in vitro activity against L. 151 monocytogenes and S. aureus (31, 32) . Although one might expect this medium to 152 broad spectrum antimicrobial peptide to cause drastic changes in the host 153 microbiome, this was in fact not the case and it was observed that the bactofencin 154 peptide only subtly modulated an ex vivo host microbiome (distal colon model) when 155
introduced as a bacteriocin producing probiotic or purified peptide. While the purified 156 peptide resulted in higher levels of beneficial microbes such as Bifidobacterium, it 157 was also associated with lower levels of Clostridium, which has been linked to 158 obesity and gut pathogenesis. Interestingly, although bactofencin does not show 159 inhibitory activity in vitro against strains from the genera Clostridium, Fusobacterium 160
and Bacteroides, the reduction of these populations in the bactofencin treated faecal 161 samples indicates that the consequence of bactofencin altering the overall microbiota 162 structure impacts, directly or indirectly, on these normally insensitive populations 163 when in the gut environment (33). 164 165 It has also been shown, using bacteriocin producing probiotic strains and their 166 isogenic mutants, that the production of bacteriocins can aid the colonisation of a 167 murine host (34). Sequencing data revealed that although bacteriocin production by 168 the probiotics did not affect bacterial diversity at the phylum level, broad spectrum 169 bacteriocins (enterocins and garvicin ML) had a more significant impact on the 170 genus/family diversity of the host microbiome than narrow spectrum bacteriocins 171 (sakacin A, plantaricins and pediocin PA-1). 172 173 Bacteriocins in animal models 174 Bacteriocins have been shown to be effective in the treatment of variety of infectious 175 bacteria using two delivery methods, either as purified peptides (Table 1) The concept of oral replacement therapy is another interesting example of 189 prophylactic probiotic therapy, which has been investigated using the mutacin 1140 190 producing streptococcus mutans BCS3-L1. This bacteriocin producing strain is 191 suitable for replacement therapy as it has reduced cariogenic potential because it does 192 not produce lactic acid, mediated through the removal of its entire lactic acid 193 dehydrogenase operon (43). Another interesting probiotic that has shown promise in the limitation of dental caries, plaque accumulation and acidification is Streptococcus 195 salivarius M18. This strain has 3 plasmid and 1 chromosomally encoded bacteriocins, 196 which is perhaps why it can colonise the oral cavity so effectively. It also produces 197 two enzymes, urease and dextranase, which reduce saliva acidity and counteract 198 plaque formation (44). In a clinical trial, both the safety and efficacy of this strain's 199 probiotic potential was demonstrated, and it was shown to significantly reduce plaque 200 formation in subjects who received the probiotic, over those who received the placebo 201 (45). Furthermore, the treatment of children who have a high risk of dental caries 202 development, with an oral formulation of the S. salivarius M18 probiotic (Carioblis ® ) 203 was shown to reduce the likelihood of new dental caries development (46). Helicobacter pylori infection and colonisation results in a variety of disease states and 237 may even lead to the development of gastric carcinoma. More recently, the prevalence 238 of antibiotic resistant H. pylori has been increasing, creating a need for a new 239 therapeutic agent (54). It has been shown in mice that eradication of H. pylori was 240 achieved using a bacteriocinogenic probiotic treatment of P. acidilactici BA28 (55). 241
Using a mixture of cranberry juice and the bacteriocin producing probiotic culture 242
Lactobacillus johnsonii str. La1 supernatant, the carriage of H. pylori was also 243 reduced in children after three weeks of treatment (56). 244
One barrier to the use of probiotics as a therapeutic is their ability to survive and 246 colonise the area of infection. It has been shown that Pediococcus acidilactici UL5 247
and Lactococcus lactis ATCC 11454 can produce the bacteriocins pediocin PA-1 and 248 nisin, respectively, in situ under simulated upper gastric conditions (57). Interestingly, 249 the in vitro activity of a bacteriocin does not always correspond to the in vivo activity, 250
where the bacteriocin is sometimes more or less active in an animal model, as is the 251 case with mersacidin which is more active in vivo than in vitro (58) . In previous decades significant emphasis was placed on functional characteristics of 297 bacteriocins, such as spectrum of activity, pH and temperature stability, which were 298 essential for the use of bacteriocins in food applications. For their use as therapeutics 299 additional characteristics such as proteolytic resistance, stability and solubility of 300 bacteriocins will also be important. 301
302
With advancements in the field of bioengineering many intrinsic limitations have 303 been overcome, and it has been shown using the prototypic lantibiotic, nisin, that 304 bioengineering strategies can improve functional qualities such as antimicrobial 305 activity (69-72), solubility (73, 74) diffusion properties (75) and effectiveness against 306
Gram-negative bacteria (71). Indeed, similar bioengineering strategies could be 307 applied to other bacteriocins once suitable expression systems have been developed. 308
Although the sensitivity of bacteriocins to proteolytic cleavage was previously 309 regarded as a desirable trait when using these peptides as food preservatives, it does 310 represent a major concern with regard to their administration and widespread use, 311 both orally and intravenously. Bioengineering strategies could be once again used to 312 manipulate peptide residues so they are no longer recognisable by host proteases and 313 therefore are not proteolytically cleaved, thereby improving peptide functional 314 qualities (76). Notably, the therapeutic application of the prototypic bacteriocin, nisin, 315 has been in part hampered by its sensitivity to host proteases (77. Other approaches 316 include prospecting for bacteriocins that display innate resistance to proteases, as was achieved with pseudomycoicidin (78), which is naturally resistant to trypsin due to the 318 presence of a thioether ring structure. The field of bioinformatics and the use of such 319 programs as BAGEL 3.0 (79) and antiSMASH (80) could be a fundamental aspect of 320 this prospecting, as these bacteriocin amino acid prediction tools from genome 321 sequences may also allow researchers to identify protease resistant peptides before 322 investing large amounts of time and effort in characterising such bacteriocins. Finally, 323
understanding bacteriocin pharmacodynamics and pharmacokinetics are also essential 324 to their safe implementation as therapeutics, which has been under investigated in 325 comparison to other aspects of bacteriocin research. If bacteriocins are indeed to 326 become an alternative to conventional antibiotics, a greater emphasis must be placed 327 on research surrounding these host-drug interactions, such as was achieved with 328 MU1140 (81). Addressing these limitations of bacteriocin research to date could 329 provide a turning point for the flagging interest of the pharmaceutical industry and 330 make bacteriocins an attractive therapeutic alternative to current antibiotics (10). 331
332
Although there is considerable evidence that narrow spectrum bacteriocins have a 333 minimal effect on the host microbiome by comparison to current broad-spectrum 334 antibiotics, it should also be recognised that more work in this regard is needed to 335 strengthen the argument for the use of bacteriocins as antibiotics, along with 336 overcoming the previously outlined limitations. Ultimately, we believe given the safe 337 history of use of bacteriocins in food and the large body of literature surrounding this 338 field, that they are useful candidates for antimicrobial therapeutics as the AMR crisis 339 continues to worsen. 340
• Antimicrobial resistance (AMR) is a major threat to public health requiring 342 immediate attention. 343
• Bacteriocins are potent antimicrobial peptides, active in the nanomolar range and 344 have a reduced impact on the host microbiota. 345
• Bacteriocins may be used to treat a broad range of infections and can be delivered 346 as purified peptides or as bacteriocinogenic probiotics. 347
• Combining antibiotics and bacteriocins is a strategy to reduce the negative 348 impacts on the host microbiota and also alleviate the AMR crisis. 349
• Overcoming the current limitations of bacteriocin-based therapeutics should be a 350 key goal of bacteriocin research in the future. 351
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